On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Pressure BioSciences, Inc. (PBIO) Receives Pivotal U.S. Patent for Novel, High-Pressure Enhanced Consumable Device

  • Pressure BioSciences develops and sells pressure-based instruments and consumables to the global life sciences, food and beverage, and other large research markets
  • Their products are based on three key technology platforms, led by their proprietary Pressure Cycling Technology (“PCT”)
  • The award of the PCT MicroPestle (“MP”) patent moves Pressure BioSciences even closer to entering the clinical diagnostics market, which is exponentially larger than the research products market where the Company currently transacts business
  • The Company utilizes a “razor: razor blade” business model, and the PCT MP is the Company’s most important and popular consumable to date
  • PBI has seen revenue from consumables steadily increase in recent years and double in just four years. The new patent provides greater security for its business model as well as potential for more explosive growth
  • Recent publications from highly regarded scientists in Australia, China, and the U.S., cite the important use of PCT and the PCT MP in critical areas of scientific research, including cancer and COVID-19 research

Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other industries, has been awarded a pivotal U.S. patent for “Sample Preparation Devices and Methods” (http://ibn.fm/WL9XC).

With this new patent, the Company continues to expand its already significant intellectual property ownership, which now includes 25 issued patents.

Pressure BioSciences’ unique pressure cycling technology (“PCT”) systems are comprised of two major, interdependent components: the pressure cycling instrument and the consumable that contains and delivers the cycled pressure to the sample. The newly patented PCT MicroPestle (“MP”) is a critical addition to the Company’s impressive instruments and consumables product line.

The PCT MP is the Company’s most important and popular consumable to date, having a unique construction that seals and protects the sample while flexing to transfer immense pressures to the important samples being processed inside the MP tube. This, in turn, facilitates homogenization and precise physical and chemical preparation of biological samples, sometimes very small and hard-to-process specimens such as needle biopsies, small suspensions of cells, and laser micro-dissected tissue sections.

The PCT MicroPestle is designed with inert fluoropolymer material, which maintains stability for the sample as it experiences significant temperature fluctuations. The PCT MP also provides powerful resistance to aggressive chemicals. Extremely low surface binding characteristics enable the PCT MP to preserve and maximize the availability of each sample’s precious molecules, which often include important biomarkers for disease diagnosis or critical prognostic decisions regarding treatment selection and guidance.

Recent publications cite the use of PCT and the PCT MP in cancer and COVID-19 research, citing the use of the Company’s products in their studies to develop better methods for the detection, prevention, and cure of infectious diseases.

Prospective Financial Impact of the New Patent

With the PCT MP, Pressure BioSciences inches all that much closer to entering the clinical market, which has exponentially larger potential than the research market, where the Company currently transacts business. With just one proven clinical application of PCT and the PCT MP, Pressure BioSciences will have enormous potential for revenue.

PCT instruments tend to heavily impact revenue up front, while consumables continue to provide revenue potential throughout the life of the instrument. Pressure BioSciences has seen revenue from consumables steadily increase in recent years and double in just the past four years, from $150K in 2015 to $260K in 2017 and then $300K in 2019. The new patent provides even more security for this kind of growth and potential for more explosive growth.

Several high-profile labs in pharma, biotech, government, and academia routinely use the PCT MP. Publications about the capabilities of PCT MP are making their way into circulation and garnering attention. This is particularly true for the processing of minute cancer biopsy tissues and other small specimens where the options for a high-quality processing method are few and far between.

Worldwide Customer Demand

According to Ms. Roxana McCloskey, Pressure BioSciences’ Global Director of Sales and Marketing, the PCT MP is already used in prominent studies such as the one conducted by Professor Phil Robinson and his team at the Children’s Medical Research Institute in Australia (processing 70,000 tumor samples, looking for prognostic and diagnostic markers in cancer) and the one run by Dr. Tiannan Guo and his team at Westlake University in China (studying thyroid cancer and COVID-19).

The PCT MP is also a critical part of the innovative laser microdissection tumor processing workflow developed by Dr. Tom Conrads of the Inova Health System in the U.S. This important new tumor processing method promises the potential for significant improvements in the clinical management of most solid tumor cancers. Dr. Conrads’ novel workflow is the basis of Pressure BioSciences’ major co-marketing collaboration recently announced with Leica Microsystems (a Danaher company).

“It is clear why we see this award of the PCT MP patent as a critical milestone in securing our pivotal intellectual property around the PCT system, and another important driver toward accelerated adoption of PCT in biological sample preparation markets. We expect to take full advantage of this opportunity and further boost our sales,” Ms. McCloskey said.

Dr. Alexander Lazarev, Pressure BioSciences’ Chief Scientific Officer, added: “This long-anticipated patent is an exciting endorsement of our efforts to transform biological sample preparation. This powerful new dimension to our patent protected portfolio should help us to secure and accelerate the growth of our business.”

For more information, visit the company’s website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered